MedTrace Logo

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

NCT02443090 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-11-13

No results posted yet for this study

Summary

To evaluate the safety and efficacy of fispemifene in men with secondary hypogonadism and sexual side effects.

Conditions

Interventions

DRUG

fispemifene

OTHER

Placebo

Sponsors & Collaborators

  • NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

    lead INDUSTRY

Principal Investigators

  • Barbara Troupin, MD, MBA · NexMed (U.S.A.), Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-10-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02443090 on ClinicalTrials.gov